Curcumin Analog Ionization for Prostate Cancer Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current curcumin analogs for treating hormone-refractory prostate cancer suffer from low bioavailability due to poor water solubility and rapid metabolism, limiting their effectiveness as cancer therapeutics.
Innovation Solution
Development of curcumin analogs with a scaffold represented by general formulas (I)-(IV), featuring a central monoketone linker bonded to two basic heteroaromatic rings, which enhance bioavailability by ionization in the stomach and deprotonation in the intestines, reducing metabolic instability and increasing water solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin analogs are administered to treat prostate cancer, then anticancer potency is improved, but bioavailability deteriorates due to poor water solubility and rapid metabolism
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of curcumin analogs through substituting phenolic hydroxyl groups with basic heteroaromatic rings. This structural modification changes the ionization properties of the compounds, enabling them to ionize in the acidic stomach environment and deprotonate in the intestinal environment, thereby improving water solubility and bioavailability while maintaining anticancer potency
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecular structures that combine the core curcumin scaffold with basic heteroaromatic ring systems. This composite approach integrates the anticancer properties of curcumin with the enhanced solubility and metabolic stability characteristics of the heteroaromatic modifications, achieving both improved potency and bioavailability
2Reliability
If curcumin analogs are administered at high doses to improve efficacy, then anticancer effect is enhanced, but metabolic stability deteriorates due to rapid in vivo metabolism
Solution Approach 1:
The patent modifies the metabolic stability parameter by replacing metabolically labile phenolic hydroxyl groups with chemically stable basic heteroaromatic rings. This parameter change in the molecular structure protects against rapid Phase II metabolism while preserving the ability to inhibit Phase I metabolizing enzymes, thereby extending the duration of action and maintaining anticancer efficacy
3Quantity of substance
If curcumin analogs are designed to improve water solubility, then bioavailability is enhanced, but potency may deteriorate due to structural modifications
Solution Approach 1:
The patent applies local quality principles by making targeted modifications only to specific functional groups (the phenolic hydroxyls) while preserving the core curcumin scaffold and its essential anticancer activity. The basic heteroaromatic rings are strategically positioned to provide solubility benefits without interfering with the molecular interactions necessary for cancer cell targeting and inhibition
Solution Approach 2:
The patent changes the ionization parameter of the molecule to improve water solubility. The basic heteroaromatic rings can accept protons in acidic environments, creating charged species that are more water-soluble. This parameter change is reversible in the intestinal environment, allowing the compound to maintain both solubility and potency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new curcumin analogs demonstrate improved potency and stability, significantly reducing the viability and growth of aggressive cancer cells, including prostate cancer cells, with enhanced bioavailability and reduced cytotoxicity to non-cancerous cells.
Implementation Method 1
enhance bioavailability by ionization in the stomach and deprotonation in the intestines
Implementation Method 2
enhance bioavailability by ionization in the stomach and deprotonation in the intestines
Data Source
AI summary
This invention relates generally to methods of treating aggressive cancers, such as hormone-refractory metastatic prostate cancer, by exposing the aggressive cancer cells to curcumin analogs having the claimed structural scaffolds and side groups. The anticancer effects of curcumin are associated with its influence on numerous growth factors within the cells. However, its clinical development has been limited by its suboptimal pharmacokinetics and poor bioavailability caused by poor solubility in water and rapid in vivo metabolism. There is the need to develop new and improved curcumin analogs with better potency, water solubility, and in vivo metabolic stability, as well as retained safety profiles. Curcumin analogs having one of the claimed four novel scaffolds with basic heteroaromatic side groups show the ability to decrease aggressive cancer cell viability and to inhibit aggressive cancer cell growth.